Resona Asset Management Co. Ltd. Has $10.59 Million Stock Position in IQVIA Holdings Inc. $IQV

Resona Asset Management Co. Ltd. lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 6.5% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 56,234 shares of the medical research company’s stock after selling 3,909 shares during the quarter. Resona Asset Management Co. Ltd.’s holdings in IQVIA were worth $10,592,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Artisan Partners Limited Partnership bought a new stake in shares of IQVIA in the 2nd quarter valued at $515,772,000. Norges Bank purchased a new position in shares of IQVIA during the second quarter valued at approximately $270,160,000. AQR Capital Management LLC grew its stake in shares of IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after acquiring an additional 879,701 shares in the last quarter. Laurel Wealth Advisors LLC grew its position in IQVIA by 15,755.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock worth $122,857,000 after purchasing an additional 774,681 shares in the last quarter. Finally, Nordea Investment Management AB lifted its holdings in IQVIA by 41.7% during the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after acquiring an additional 606,391 shares during the period. 89.62% of the stock is owned by institutional investors.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares in the company, valued at $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

IQV has been the topic of a number of research reports. Robert W. Baird set a $258.00 price target on shares of IQVIA and gave the stock an “outperform” rating in a report on Wednesday, October 29th. Mizuho set a $266.00 price objective on shares of IQVIA in a research report on Friday, January 9th. BMO Capital Markets started coverage on IQVIA in a research report on Thursday, November 13th. They set an “outperform” rating and a $260.00 target price for the company. HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and increased their price target for the stock from $195.00 to $235.00 in a report on Thursday, October 9th. Finally, Barclays set a $230.00 target price on IQVIA in a research report on Monday, December 15th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $251.06.

IQVIA Price Performance

IQV opened at $239.28 on Tuesday. The stock has a 50-day moving average price of $229.57 and a 200-day moving average price of $206.73. The firm has a market cap of $40.75 billion, a PE ratio of 32.82, a P/E/G ratio of 2.39 and a beta of 1.36. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $247.04. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating the consensus estimate of $2.98 by $0.02. The firm had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.84 earnings per share. Sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.